3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Stomach Neoplasms
2
Small Cell Lung Carcinoma
1
Pleural Effusion, Malignant
1
MET Positive
1
Lung Neoplasms
1
Interventions
talimogene laherparepvec
1
rilotumumab
1
lipoplatin
1
ganitumab
1
cediranib
1
Zoledronic Acid
1
Verteporfin
1
Thoracentesis
1
Therapeutics
1
Talc
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Spectrum Analysis
1
Sodium Chloride
1
SPI-77, liposomal
1
Radiotherapy, Conformal
1
Photochemotherapy
1
Nivolumab
1
Naproxen
1
Immunohistochemistry
1
Fluorodeoxyglucose F18
1
Fentanyl
1
Etoposide
1
Drug Therapy
1
Doxycycline
1
Dihematoporphyrin Ether
1
Darbepoetin alfa
1
Coal Tar
1
Cisplatin
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Pleural Effusion, Malignant
×
rilotumumab
×
Clear all
NCT00791154
2024-08-23
SCLC
NantCell, Inc.
Phase 1/2
Terminated
213 enrolled
16 charts